247 related articles for article (PubMed ID: 26093657)
1. Developments in cancer vaccines for hepatocellular carcinoma.
Buonaguro L;
Cancer Immunol Immunother; 2016 Jan; 65(1):93-9. PubMed ID: 26093657
[TBL] [Abstract][Full Text] [Related]
2. Phase I/II Multicenter Trial of a Novel Therapeutic Cancer Vaccine, HepaVac-101, for Hepatocellular Carcinoma.
Löffler MW; Gori S; Izzo F; Mayer-Mokler A; Ascierto PA; Königsrainer A; Ma YT; Sangro B; Francque S; Vonghia L; Inno A; Avallone A; Ludwig J; Alcoba DD; Flohr C; Aslan K; Mendrzyk R; Schuster H; Borrelli M; Valmori D; Chaumette T; Heidenreich R; Gouttefangeas C; Forlani G; Tagliamonte M; Fusco C; Penta R; Iñarrairaegui M; Gnad-Vogt U; Reinhardt C; Weinschenk T; Accolla RS; Singh-Jasuja H; Rammensee HG; Buonaguro L
Clin Cancer Res; 2022 Jun; 28(12):2555-2566. PubMed ID: 35421231
[TBL] [Abstract][Full Text] [Related]
3. Challenges in cancer vaccine development for hepatocellular carcinoma.
Buonaguro L; Petrizzo A; Tagliamonte M; Tornesello ML; Buonaguro FM
J Hepatol; 2013 Oct; 59(4):897-903. PubMed ID: 23714157
[TBL] [Abstract][Full Text] [Related]
4. Novel metronomic chemotherapy and cancer vaccine combinatorial strategy for hepatocellular carcinoma in a mouse model.
Tagliamonte M; Petrizzo A; Napolitano M; Luciano A; Arra C; Maiolino P; Izzo F; Tornesello ML; Aurisicchio L; Ciliberto G; Buonaguro FM; Buonaguro L
Cancer Immunol Immunother; 2015 Oct; 64(10):1305-14. PubMed ID: 25944003
[TBL] [Abstract][Full Text] [Related]
5. Peptide vaccines for hepatocellular carcinoma.
Nobuoka D; Yoshikawa T; Sawada Y; Fujiwara T; Nakatsura T
Hum Vaccin Immunother; 2013 Jan; 9(1):210-2. PubMed ID: 23442593
[TBL] [Abstract][Full Text] [Related]
6. Immunobiology and gene-based immunotherapy of hepatocellular carcinoma.
Geissler M; Mohr L; Ali MY; Grimm CF; Ritter M; Blum HE
Z Gastroenterol; 2003 Nov; 41(11):1101-10. PubMed ID: 14648380
[TBL] [Abstract][Full Text] [Related]
7. Tackling hepatocellular carcinoma with individual or combinatorial immunotherapy approaches.
Tagliamonte M; Mauriello A; Cavalluzzo B; Ragone C; Manolio C; Petrizzo A; Buonaguro L
Cancer Lett; 2020 Mar; 473():25-32. PubMed ID: 31875523
[TBL] [Abstract][Full Text] [Related]
8. The spontaneous CD8+ T-cell response to HLA-A2-restricted NY-ESO-1b peptide in hepatocellular carcinoma patients.
Shang XY; Chen HS; Zhang HG; Pang XW; Qiao H; Peng JR; Qin LL; Fei R; Mei MH; Leng XS; Gnjatic S; Ritter G; Simpson AJ; Old LJ; Chen WF
Clin Cancer Res; 2004 Oct; 10(20):6946-55. PubMed ID: 15501973
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic Vaccines against Hepatocellular Carcinoma in the Immune Checkpoint Inhibitor Era: Time for Neoantigens?
Repáraz D; Aparicio B; Llopiz D; Hervás-Stubbs S; Sarobe P
Int J Mol Sci; 2022 Feb; 23(4):. PubMed ID: 35216137
[TBL] [Abstract][Full Text] [Related]
10. Immunotherapeutic approaches for hepatocellular carcinoma.
Longo V; Gnoni A; Casadei Gardini A; Pisconti S; Licchetta A; Scartozzi M; Memeo R; Palmieri VO; Aprile G; Santini D; Nardulli P; Silvestris N; Brunetti O
Oncotarget; 2017 May; 8(20):33897-33910. PubMed ID: 28420805
[TBL] [Abstract][Full Text] [Related]
11. Combinatorial immunotherapy strategies for hepatocellular carcinoma.
Tagliamonte M; Petrizzo A; Tornesello ML; Ciliberto G; Buonaguro FM; Buonaguro L
Curr Opin Immunol; 2016 Apr; 39():103-13. PubMed ID: 26851637
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of the interest to combine a CD4 Th1-inducer cancer vaccine derived from telomerase and atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma: a randomized non-comparative phase II study (TERTIO - PRODIGE 82).
Vienot A; Jacquin M; Rebucci-Peixoto M; Pureur D; Ghiringhelli F; Assenat E; Hammel P; Rosmorduc O; Stouvenot M; Allaire M; Bouattour M; Regnault H; Fratte S; Raymond E; Soularue E; Husson-Wetzel S; Di Martino V; Muller A; Clairet AL; Fagnoni-Legat C; Adotevi O; Meurisse A; Vernerey D; Borg C
BMC Cancer; 2023 Jul; 23(1):710. PubMed ID: 37516867
[TBL] [Abstract][Full Text] [Related]
13. Alpha fetoprotein is more than a hepatocellular cancer biomarker: from spontaneous immune response in cancer patients to the development of an AFP-based cancer vaccine.
Bei R; Mizejewski GJ
Curr Mol Med; 2011 Oct; 11(7):564-81. PubMed ID: 21707514
[TBL] [Abstract][Full Text] [Related]
14. Immunotherapy for Hepatocellular Carcinoma: Current Status and Future Prospects.
Liu Z; Liu X; Liang J; Liu Y; Hou X; Zhang M; Li Y; Jiang X
Front Immunol; 2021; 12():765101. PubMed ID: 34675942
[TBL] [Abstract][Full Text] [Related]
15. Strategies to Improve the Antitumor Effect of Immunotherapy for Hepatocellular Carcinoma.
Xing R; Gao J; Cui Q; Wang Q
Front Immunol; 2021; 12():783236. PubMed ID: 34899747
[TBL] [Abstract][Full Text] [Related]
16. Immunotherapy for hepatocellular carcinoma.
Li S; Yang F; Ren X
Drug Discov Ther; 2015 Oct; 9(5):363-71. PubMed ID: 26632545
[TBL] [Abstract][Full Text] [Related]
17. Aspartate-β-hydroxylase induces epitope-specific T cell responses in hepatocellular carcinoma.
Tomimaru Y; Mishra S; Safran H; Charpentier KP; Martin W; De Groot AS; Gregory SH; Wands JR
Vaccine; 2015 Mar; 33(10):1256-66. PubMed ID: 25629522
[TBL] [Abstract][Full Text] [Related]
18. Potentiality of immunotherapy against hepatocellular carcinoma.
Tsuchiya N; Sawada Y; Endo I; Uemura Y; Nakatsura T
World J Gastroenterol; 2015 Sep; 21(36):10314-26. PubMed ID: 26420958
[TBL] [Abstract][Full Text] [Related]
19. Perspectives of immunotherapy in hepatocellular carcinoma (HCC).
Büttner N; Schmidt N; Thimme R
Z Gastroenterol; 2016 Dec; 54(12):1334-1342. PubMed ID: 27936483
[TBL] [Abstract][Full Text] [Related]
20. [Usefulness of a novel oncofetal antigen, glypican-3, for diagnosis and immunotherapy of hepatocellular carcinoma].
Nishimura Y; Nakatsura T; Senju S
Nihon Rinsho Meneki Gakkai Kaishi; 2008 Oct; 31(5):383-91. PubMed ID: 18974622
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
